FrancophonIA/ELRC3.0 huggingface dataset:
English: For up to 52 weeks, the frequency of ALT and AST elevations ≥ 3 x ULN were greater for the combination treatment of methotrexate and Olumiant (7.5 % and 3.8 %) compared to methotrexate alone (2.9 % and 0.5 %) or Olumiant alone (1.9 % and 1.3 %).
Danish: Over de første 52 uger var hyppigheden af forhøjet ALAT og ASAT til ≥ 3 x ULN højere ved behandling med methotrexat og Olumiant i kombination (7,5 % og 3,8 %) sammenlignet med methotrexat alene (2,9 % og 0,5 %) og Olumiant alene (1,9 % og 1,3 %).
English: Week 52 1.02 0.80 0.40**
Danish: Uge 52 1,02 0,80 0,40**
English: The pattern and incidence of elevation in ALT/AST remained stable over time including in the longterm extension study.
Danish: Mønsteret på og incidensen af forhøjet ALAT/ASAT forblev stabilt over tid, herunder i det længerevarende forlængelsesstudie.
English: ALT increased ≥3 x ULNc AST increased ≥3 x ULNc
Danish: ALAT ≥ 3 x ULNc
English: Olumiant is not recommended for use in patients with severe hepatic impairment (see section 5.2).
Danish: Det anbefales ikke at anvende Olumiant til patienter med svært nedsat leverfunktion (se pkt.
English: Treatment should be interrupted if ANC < 1 x 109 cells/L and may be restarted once ANC return above this value
Danish: Behandlingen bør afbrydes ved ANC < 1 x 109 celler/l og kan genoptages, når ANC igen er over denne værdi.
English: • iron oxide red (E172)
Danish: • rødt jernoxid (E 172)
English: Driving and using machines Olumiant has no effect on the ability to drive and use machines.
Danish: Trafik- og arbejdssikkerhed Olumiant påvirker ikke evnen til at føre motorkøretøj og betjene maskiner.
English: Gastric pH modifying agents Elevating gastric pH with omeprazole had no clinically significant effect on baricitinib exposure.
Danish: Øgning af gastrisk pH med omeprazol havde ingen klinisk signifikant effekt på eksponeringen for baricitinib.
English: Week 24 0.61 0.39 0.29*
Danish: Uge 24 0,61 0,39 0,29*
English: For most patients, changes in lymphocyte count occurred within the normal reference range.
Danish: Hos de fleste patienter lå lymfocyttallet fortsat inden for det normale referenceinterval.
English: Coadministration of baricitinib with fluconazole (moderate CYP3A/CYP2C19/CYP2C9 inhibitor) or rifampicin (strong CYP3A inducer) resulted in no clinically meaningful changes to baricitinib exposure.
Danish: Samtidig administration af baricitinib og fluconazol (moderat CYP3A-/CYP2C19-/CYP2C9-hæmmer) eller rifampicin (potent CYP3A-induktor) resulterede ikke i nogen klinisk relevante ændringer i eksponeringen for baricitinib.
English: Coadministration of baricitinib with ciclosporin (Pgp/BCRP inhibitor) or methotrexate (substrate of several transporters including OATP1B1, OAT1, OAT3, BCRP, MRP2, MRP3, and MRP4) resulted in no clinically meaningful effects on baricitinib exposure.
Danish: Samtidig administration af baricitinib og ciclosporin (Pgp-/BCRP-hæmmer) eller methotrexat (substrat for flere transportører, herunder OATP1B1, OAT1, OAT3, BCRP, MRP2, MRP3 og MRP4) resulterede ikke i nogen klinisk relevante effekter på eksponeringen for baricitinib.
English: Renal function was found to significantly affect baricitinib exposure.
Danish: Det er vist, at nyrefunktionen påvirker eksponeringen for baricitinib signifikant.
English: Treatment should be started by a doctor experienced in the diagnosis and treatment of rheumatoid arthritis.
Danish: Behandlingen skal startes af en læge med erfaring i diagnosticering og behandling af leddegigt.
English: Olumiant 2 mg and 4 mg are available in blister packs of 14, 28, 35, 56, 84 and 98 tablets in calendar blisters and 28 x 1 and 84 x 1 tablets in perforated unit dose blisters.
Danish: Tabletterne er afrundede og har udhulede sider, så de er nemmere at tage op. Olumiant 2 mg og 4 mg fås i blisterpakninger med 14, 28, 35, 56, 84 og 98 tabletter i kalender-blistere og 28 x 1 og 84 x 1 tabletter i perforerede enkeltdosis-blistere.
English: Week 52 0.81 0.55 0.34**
Danish: Uge 52 0,81 0,55 0,34**
English: The mean ratios of AUC in patients with mild and moderate renal impairment to patients with normal renal function are 1.41 (90 % CI: 1.15-1.74) and 2.22 (90 % CI: 1.81-2.73), respectively.
Danish: Den gennemsnitlige ratio mellem AUC hos patienter med henholdsvis let og moderat nedsat nyrefunktion og patienter med normal nyrefunktion er henholdsvis 1,41 (90 % CI: 1,15-1,74) og 2,22 (90 % CI: 1,81-2,73).
English: The mean ratios of Cmax in patients with mild and moderate renal impairment to patients with normal renal function are 1.16 (90 %CI: 0.92-1.45) and 1.46 (90 %CI: 1.17-1.83), respectively.
Danish: Den gennemsnitlige ratio mellem Cmax hos patienter med henholdsvis let og moderat nedsat nyrefunktion og patienter med normal nyrefunktion er henholdsvis 1,16 (90 % CI: 0,92-1,45) og 1,46 (90 % CI: 1,17-1,83).
English: • Increased triglycerides ≥ 5.65 mmol/L: 0.4 % vs. 0.5 %, respectively
Danish: • Stigning i triglycerider til ≥ 5,65 mmol/l: 0,4 % vs. 0,5 %
English: The proportion of patients achieving a clinically significant improvement (HAQ-DI ≥ 0.30) was also higher with Olumiant compared to placebo or MTX at week 12 (Table 4).
Danish: Andelen af patienter, der opnåede en klinisk signifikant forbedring (HAQ-DI ≥ 0,30) i uge 12, var også højere med Olumiant sammenlignet med placebo og MTX (tabel 4).
English: If an infection develops, the patient should be monitored carefully and Olumiant therapy should be temporarily interrupted if the patient is not responding to standard therapy.
Danish: Hvis en infektion udvikles, skal patienten overvåges nøje, og hvis patienten ikke responderer på standardbehandling, skal behandlingen med Olumiant afbrydes midlertidigt.
English: INFORMATION IN BRAILLE Olumiant 2 mg
Danish: INFORMATION I BRAILLESKRIFT Olumiant 2 mg
English: Treatment should not be initiated, or should be temporarily interrupted, in patients with an ANC < 1 x 109 cells/L, ALC < 0.5 x 109 cells/L or haemoglobin < 8 g/dL observed during routine patient management (see section 4.2).
Danish: Behandling bør ikke indledes eller bør midlertidigt afbrydes hos patienter med ANC < 1 x 109 celler/l, ALC < 0,5 x 109 celler/l eller hæmoglobin < 4,96 mmol/l observeret i forbindelse med den rutinemæssige kontrol af patienterne (se pkt.
English: Treatment should be interrupted if ALC < 0.5 x 109 cells/L and may be restarted once ALC return above this value
Danish: Behandlingen bør afbrydes ved ALC < 0,5 x 109 celler/l og kan genoptages, når ALC igen er over denne værdi.
English: INFORMATION IN BRAILLE Olumiant 4 mg
Danish: INFORMATION I BRAILLESKRIFT Olumiant 4 mg
English: Neutropaenia
Danish: Neutropeni
English: • Additional Patient Alert Cards
Danish: • Ekstra patientkort
English: - The other ingredients are: microcrystalline cellulose, croscarmellose sodium, magnesium stearate, mannitol, iron oxide red (E172), lecithin (soya) (E322), macrogol, poly (vinyl alcohol), talc and titanium dioxide (E171).
Danish: mannitol, rødt jernoxid (E 172), lecithin (soja) (E 322), macrogol, polyvinylalkohol, talcum og titandioxid (E 171).
English: • Increased LDL cholesterol ≥ 3.36 mmol/L: 33.6 % vs. 10.3 %, respectively
Danish: • Stigning i LDL-kolesterol til ≥ 3,36 mmol/l: 33,6 % vs. 10,3 %
English: EU/1/16/1170/001 (14 film-coated tablets) EU/1/16/1170/002 (28 film-coated tablets) EU/1/16/1170/003 (28 x 1 film-coated tablets) EU/1/16/1170/004 (35 film-coated tablets) EU/1/16/1170/005 (56 film-coated tablets) EU/1/16/1170/006 (84 film-coated tablets) EU/1/16/1170/007 (84 x 1 film-coated tablets) EU/1/16/1170/008 (98 film-coated tablets)
Danish: EU/1/16/1170/001 (14 filmovertrukne tabletter) EU/1/16/1170/002 (28 filmovertrukne tabletter) EU/1/16/1170/003 (28 x 1 filmovertrukne tabletter) EU/1/16/1170/004 (35 filmovertrukne tabletter) EU/1/16/1170/005 (56 filmovertrukne tabletter) EU/1/16/1170/006 (84 filmovertrukne tabletter) EU/1/16/1170/007 (84 x 1 filmovertrukne tabletter) EU/1/16/1170/008 (98 filmovertrukne tabletter)
English: In RA-BEAM and RA-BUILD, treatment with Olumiant 4 mg resulted in a significant improvement in the mean duration and severity of morning joint stiffness compared to placebo or adalimumab as assessed using daily electronic patient diaries for 12 weeks.
Danish: I RA-BEAM og RA-BUILD resulterede behandling med Olumiant 4 mg i en signifikant reduktion af den gennemsnitlige varighed og sværhedsgrad af morgenstivhed i og omkring led i uge 12 sammenlignet med placebo og adalimumab vurderet ud fra patienternes daglige rapporteringer i elektroniske dagbøger.
English: In a combined male/female rat fertility study, baricitinib decreased overall mating performance (decreased fertility and conception indices).
Danish: I et fertilitetsstudie med både han- og hunrotter nedsatte baricitinib den samlede parringsevne (nedsatte fertilitets- og konceptionsindekser).
English: • croscarmellose sodium
Danish: • croscarmellosenatrium
English: • At week 12: 234/251 (93 %) continuing 4 mg vs. 207/251 (82 %) reduced to 2 mg (p ≤ 0.001)
Danish: • Ved uge 12: 234/251 (93 %), der fortsatte med 4 mg, vs. 207/251 (82 %), som fik reduceret dosis til 2 mg (p ≤ 0,001)
English: EU/1/16/1170/009 (14 film-coated tablets) EU/1/16/1170/010 (28 film-coated tablets) EU/1/16/1170/011 (28 x 1 film-coated tablets) EU/1/16/1170/012 (35 film-coated tablets) EU/1/16/1170/013 (56 film-coated tablets) EU/1/16/1170/014 (84 film-coated tablets) EU/1/16/1170/015 (84 x 1 film-coated tablets) EU/1/16/1170/016 (98 film-coated tablets)
Danish: EU/1/16/1170/009 (14 filmovertrukne tabletter) EU/1/16/1170/010 (28 filmovertrukne tabletter) EU/1/16/1170/011 (28 x 1 filmovertrukne tabletter) EU/1/16/1170/012 (35 filmovertrukne tabletter) EU/1/16/1170/013 (56 filmovertrukne tabletter) EU/1/16/1170/014 (84 filmovertrukne tabletter) EU/1/16/1170/015 (84 x 1 filmovertrukne tabletter) EU/1/16/1170/016 (98 filmovertrukne tabletter)
English: In vitro, baricitinib is a substrate for CYP3A4, OAT3, Pgp, BCRP and MATE2-K, and may be a clinically relevant inhibitor of the transporter OCT1 (see section 4.5).
Danish: In vitro er baricitinib substrat for CYP3A4, OAT3, Pgp, BCRP og MATE2-K og kan være en klinisk relevant hæmmer af transportøren OCT1 (se pkt.
English: Olumiant is for oral use.
Danish: Olumiant skal tages gennem munden (oralt).
English: • Prescribers should screen the patients for viral hepatitis before commencing Olumiant treatment.
Danish: • Ordinerende læge skal screene patienten for at udelukke viral hepatitis og aktiv tuberkulose, før behandlingen med Olumiant indledes.
English: Lipid elevations
Danish: Stigning i lipidniveauer
English: Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s)
Danish: BILAG IV VIDENSKABELIGE KONKLUSIONER OG BEGRUNDELSER FOR ÆNDRING AF BETINGELSERNE FOR MARKEDSFØRINGSTILLADELSEN/-TILLADELSERNE
English: Treatment with Olumiant 4 mg, alone or in combination with cDMARDs, resulted in significant improvements in all individual ACR components, including tender and swollen joint counts, patient and physician global assessments, HAQ-DI, pain assessment and CRP, compared to placebo or MTX monotherapy.
Danish: Behandling med Olumiant 4 mg alene eller i kombination med cDMARDs resulterede i signifikante forbedringer i alle individuelle ACR-komponenter, herunder antal ømme og hævede led, patientens og lægens samlede vurderinger, HAQ-DI, smertevurdering og CRP, sammenlignet med placebo eller monoterapi med MTX.
English: • At week 48: 57/73 (78 %) continuing 4 mg vs. 51/86 (59 %) reduced to 2 mg (p ≤ 0.05)
Danish: • Ved uge 48: 57/73 (78 %), der fortsatte med 4 mg, vs. 51/86 (59 %), som fik reduceret dosis til 2 mg (p ≤ 0,05)
English: Absolute Neutrophil Count (ANC) < 1 x 109 cells/L, Absolute Lymphocyte Count (ALC) < 0.5 x 109 cells/L and haemoglobin < 8 g/dL were reported in less than 1 % of patients in clinical trials.
Danish: Absolut neutrofiltal (ANC) < 1 x 109 celler/l, absolut lymfocyttal (ALC) < 0,5 x 109 celler/l og hæmoglobin < 4,96 mmol/l blev rapporteret hos under 1 % af patienterne i kliniske studier.
English: tacrolimus or ciclosporin - other medicines belonging to the group of Janus kinase inhibitors, such as ruxolitinib
Danish: - andre lægemidler, der tilhører gruppen af Janus-kinase-hæmmere, f.eks. ruxolitinib.
English: 1 Patients who had received less than 3 doses of Methotrexate (MTX); naïve to other conventional or biologic DMARDs
Danish: 1Patienter, der havde fået mindre end 3 doser MTX og ikke tidligere var blevet behandlet med andre konventionelle eller biologiske DMARDs.
English: • At week 24: 163/191 (85 %) continuing 4 mg vs. 144/189 (76 %) reduced to 2 mg (p ≤ 0.05)
Danish: • Ved uge 24: 163/191 (85 %), der fortsatte med 4 mg, vs. 144/189 (76 %), som fik reduceret dosis til 2 mg (p ≤ 0,05)
English: Physicians should advise women of child bearing potential to use contraception during treatment and for a week after its ending.
Danish: Lægen skal informere fertile kvinder om at anvende prævention under behandlingen og mindst en uge efter ophør.
English: In controlled studies, for up to 16 weeks, alanine transaminase (ALT) and aspartate transaminase (AST) elevations ≥ 3 x upper limit of normal (ULN) were observed in 1.4 % and 0.8 % of patients treated with Olumiant, compared to 1.0 % and 0.8 % respectively of patients treated with placebo.
Danish: I kontrollerede studier blev der over de første 16 uger observeret stigning i alaninaminotransferase (ALAT) og aspartat-aminotransferase (ASAT) til ≥ 3 x den øvre normalgrænse (ULN) hos 1,4 % og 0,8 % af de patienter, der blev behandlet med Olumiant, sammenlignet med henholdsvis 1,0 % og 0,8 % af de patienter, der fik placebo.
English: Elevations in LDL cholesterol decreased to pre-treatment levels in response to statin therapy.
Danish: Som respons på statinbehandling faldt forhøjet LDL-kolesterol til det niveau, der var før behandling.
English: Deep Vein Thrombosis
Danish: Dyb venetrombose
English: Women of childbearing potential have to use effective contraception during and for at least 1 week after treatment.
Danish: Fertile kvinder skal anvende sikker kontraception under behandlingen og i mindst 1 uge efter afsluttet behandling.
English: The most commonly reported adverse drug reactions (ADRs) occurring in ≥ 2 % of patients treated with Olumiant monotherapy or in combination with conventional synthetic DMARDs were increased LDL cholesterol (33.6 %), upper respiratory tract infections (14.7 %) and nausea (2.8 %).
Danish: Olumiant som monoterapi eller i kombination med konventionelle syntetiske DMARDs, var forhøjet LDL-kolesterol (33,6 %), infektioner i øvre luftveje (14,7 %) og kvalme (2,8 %).
English: In clinical pharmacology studies, coadministration of baricitinib with the CYP3A substrates simvastatin, ethinyl oestradiol, or levonorgestrel resulted in no clinically meaningful changes in the PK of these medicinal products.
Danish: I klinisk farmakologiske studier resulterede samtidig administration af baricitinib og CYP3Asubstraterne simvastatin, ethinylestradiol eller levonorgestrel ikke i nogen klinisk relevante ændringer i farmakokinetikken for disse lægemidler.
English: In studies which included both doses, a dose-relationship was observed with increased total cholesterol ≥ 5.17 mmol/L reported in 48.8 %, 34.7 % and 17.8 % of patients up to 16 weeks in the 4 mg, 2 mg and placebo groups, respectively.
Danish: I studier, som omfattede begge doser, blev der over de første 16 uger observeret en dosisrelateret sammenhæng i stigning i totalkolesterol til ≥ 5,17 mmol/l, der blev rapporteret hos 48,8 %, 34,7 % og 17,8 % af patienterne i henholdsvis 4 mg-gruppen, 2 mg-gruppen og placebogruppen.
English: Erosion Score, Mean change from baseline:
Danish: Erosionsscore - gennemsnitlig ændring i forhold til baseline:
English: Olumiant 4 mg film-coated tablets are medium pink, round tablets, with “Lilly” on one side and “4” on the other.
Danish: Olumiant 4 mg filmovertrukne tabletter er medium pink, runde tabletter med “Lilly” på den ene side og “4” på den anden.
English: What Olumiant contains - The active substance is baricitinib.
Danish: Olumiant indeholder: - Aktivt stof: baricitinib.
English: In all studies, patients treated with Olumiant 4 mg once daily had statistically significantly higher ACR20, ACR50 and ACR70 response at 12 weeks compared to placebo, MTX or adalimumab (see Table 4).Time to onset of efficacy was rapid across measures with significantly greater responses seen as early as week 1.
Danish: I alle studier havde de patienter, der blev behandlet med Olumiant 4 mg én gang daglig, statistisk signifikant højere ACR20-, ACR50- og ACR70-responser ved uge 12 sammenlignet med placebo, MTX eller adalimumab (se tabel 4).
English: NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER Eli Lilly Nederland B.V., Papendorpseweg 83, 3528BJ Utrecht, The Netherlands.
Danish: NAVN OG ADRESSE PÅ INDEHAVEREN AF MARKEDSFØRINGSTILLADELSEN Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, Holland.
English: In studies which included both doses, infections were reported in 31.9%, 28.8% and 24.1% of patients up to 16 weeks in the 4 mg, 2 mg and placebo groups, respectively.
Danish: I studier, som omfattede begge doser, blev der over de første 16 uger rapporteret infektioner hos 31,9 %, 28,8 % og 24,1 % af patienterne i henholdsvis 4 mg-gruppen, 2 mg-gruppen og placebogruppen.
English: The pattern and incidence of decreases in neutrophil counts remained stable at a lower value than baseline over time including in the long-term extension study.
Danish: Mønsteret på og incidensen af nedsat neutrofiltal forblev stabilt - med et lavere neutrofiltal end ved baseline - over tid, herunder i det længerevarende forlængelsesstudie.
English: • Morning Joint Stiffness
Danish: • Morgenstivhed i og omkring led
English: In controlled studies, for up to 16 weeks, decreases in neutrophil counts below 1 x 109 cells/L occurred in 0.3 % of patients treated with Olumiant compared to 0 % of patients treated with placebo.
Danish: I kontrollerede studier forekom der over de første 16 uger fald i neutrofiltallet til under 1 x 109 celler/l hos 0,3 % af de patienter, der blev behandlet med Olumiant, sammenlignet med 0 % af de patienter, der fik placebo.
English: Common side effects (may affect up to 1 in 10 people): - cold sores (herpes simplex) - infection causing a sick stomach or diarrhoea (gastroenteritis) - urinary infection - pneumonia - high number of platelets (cells involved in blood clotting), shown by blood test - feeling sick in the stomach (nausea) - high levels of liver enzymes, shown by blood test - rash
Danish: Almindelige bivirkninger (kan forekomme hos op til 1 ud af 10 behandlede): - forkølelsessår (herpes simplex) - infektion, der giver kvalme, opkastning eller diarré (gastroenteritis) - urinvejsinfektion - lungebetændelse - højt antal blodplader (celler, der hjælper med at få blodet til at størkne), påvises i en blodprøve
English: In controlled studies, for up to 16 weeks, increases in CPK values were common.
Danish: I kontrollerede studier var forhøjet kreatinkinase almindeligt over de første 16 uger.
English: • Increased total cholesterol ≥ 5.17 mmol/L: 49.1 % vs.15.8 %, respectively
Danish: • Stigning i totalkolesterol til ≥ 5,17 mmol/l: 49,1 % vs. 15,8 %
English: In treatment-naïve patients, for up to 52 weeks, the frequency of upper respiratory tract infections was greater for the combination treatment of methotrexate and Olumiant (26.0 %) compared to methotrexate alone (22.9 %) or Olumiant alone (22.0 %).
Danish: Hos tidligere ubehandlede patienter var hyppigheden af infektioner i øvre luftveje over de første 52 uger højere ved behandling med methotrexat og Olumiant i kombination (26,0 %) sammenlignet med methotrexat alene (22,9 %) og Olumiant alene (22,0 %).
English: In treatment-naïve patients, through 52 weeks, the frequency of nausea was greater for the combination treatment of methotrexate and Olumiant (9.3 %) compared to methotrexate alone (6.2 %) or Olumiant alone (4.4 %).
Danish: Hos tidligere ubehandlede patienter var hyppigheden af kvalme over de første 52 uger højere ved behandling med methotrexat og Olumiant i kombination (9,3 %) sammenlignet med methotrexat alene (6,2 %) og Olumiant alene (4,4 %).
English: MARKETING AUTHORISATION HOLDER Eli Lilly Nederland B.V., Papendorpseweg 83, 3528BJ Utrecht, The Netherlands.
Danish: INDEHAVER AF MARKEDSFØRINGSTILLADELSEN Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, Holland.
English: • Increased HDL cholesterol ≥ 1.55 mmol/L: 42.7 % vs. 13.8 %, respectively
Danish: • Stigning i HDL-kolesterol til ≥ 1,55 mmol/l: 42,7 % vs. 13,8 %
English: Light pink, 9.0 x 7.5 mm oblong tablets, debossed with “Lilly” on one side and “2” on the other.
Danish: Svagt pink, 9,0 x 7,5 mm aflange tabletter, præget med “Lilly” på den ene side og “2” på den anden.
English: In vitro, baricitinib is not an inhibitor of OAT1, OAT2, OAT3, organic cationic transporter (OCT) 2, OATP1B1, OATP1B3, BCRP, MATE1 and MATE2-K at clinically relevant concentrations.
Danish: In vitro er baricitinib ikke en hæmmer af OAT1, OAT2, OAT3, organisk kation-transportør (OCT) 2, OATP1B1, OATP1B3, BCRP, MATE1 og MATE2-K ved klinisk relevante koncentrationer.
English: Baricitinib is not an inhibitor of the transporters OAT1, OAT2, OAT3, OCT2, OATP1B1, OATP1B3, BCRP, MATE1 and MATE2-K at clinically relevant concentrations.
Danish: Baricitinib er ikke en hæmmer af transportørerne OAT1, OAT2, OAT3, OCT2, OATP1B1, OATP1B3, BCRP, MATE1 og MATE2-K ved klinisk relevante koncentrationer.
English: Medium pink, 8.5 mm round tablets, debossed with “Lilly” on one side and “4” on the other.
Danish: Medium pink, 8,5 mm runde tabletter, præget med “Lilly” på den ene side og “4” på den anden.
English: Olumiant 4 mg film-coated tablets Each film-coated tablet contains 4 mg baricitinib.
Danish: Olumiant 4 mg filmovertrukne tabletter Hver filmovertrukken tablet indeholder 4 mg baricitinib.
English: • Olumiant 4 mg QD + MTX
Danish: • Olumiant 4 mg daglig + MTX
English: In clinical pharmacology studies, coadministration of baricitinib with ketoconazole (strong CYP3A inhibitor) resulted in no clinically meaningful effect on the PK of baricitinib.
Danish: I klinisk farmakologiske studier resulterede samtidig administration af baricitinib og ketoconazol (potent CYP3A-hæmmer) ikke i nogen klinisk relevant effekt på baricitinibs farmakokinetik.
English: Marketing Authorisation Holder and Manufacturer Marketing Authorisation Holder: Eli Lilly Nederland B.V., Papendorpseweg 83, 3528BJ, Utrecht, The Netherlands.
Danish: Indehaver af markedsføringstilladelsen og fremstiller Indehaver af markedsføringstilladelsen: Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, Holland.
English: • Signs or symptoms of infections including general symptoms, and specifically tuberculosis and herpes zoster signs and symptoms; and a warning for the patients to seek immediate medical attention if signs or symptoms suggesting infection appear
Danish: • Tegn eller symptomer på infektion, inklusive generelle symptomer, og specifikt symptomer på herpes zoster og tuberkulose.
English: Treatment should not be initiated in patients with an absolute lymphocyte count (ALC) less than 0.5 x 109 cells/L, an absolute neutrophil count (ANC) less than 1 x 109 cells/L, or who have a haemoglobin value less than 8 g/dL.
Danish: Behandling bør ikke indledes hos patienter med absolut lymfocyttal (ALC) < 0,5 x 109 celler/l, absolut neutrofiltal (ANC) < 1 x 109 celler/l eller med hæmoglobin < 4,96 mmol/l (8 g/dl).
English: In controlled studies, for up to 16 weeks, increases in platelet counts above 600 x 109 cells/L occurred in 2.0 % of patients treated with Olumiant 4 mg and 1.1 % of patients treated with placebo.
Danish: I kontrollerede studier forekom der over de første 16 uger stigninger i trombocyttallet til over 600 x 109 celler/l hos 2,0 % af de patienter, der blev behandlet med Olumiant 4 mg, og 1,1 % af de patienter, der fik placebo.